Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia

References

• StegPGBhattDLWilsonPWOne-year cardiovascular event rates in outpatients with atherothrombosisJAMA20072971197120617374814
   PubMed Web of Science ®Google Scholar
• HanssonGKInflammation, atherosclerosis and coronary artery diseaseN Engl J Med20053521685169515843671
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsKearneyPMBlackwellLCollinsREfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysisLancet200837111712518191683
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation200411022723915249516
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical PracticeEur Heart J2007282375241417726041
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of Medical Care in Diabetes – 2009Diab Care200932S1S13S61
   PubMedGoogle Scholar
• AltschulRHofferAStephenJDInfluence of nicotinic acid on serum cholesterol in manArch Biochem19555455855914350806
   PubMed Web of Science ®Google Scholar
• VogtAKassnerUHostalekUEvaluations of safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS StudyCurr Med Res Opin20062241742516466614
   PubMed Web of Science ®Google Scholar
• ShepherdJPackardDJPatschJREffects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoptotein A metabolismJ Clin Invest197963858867221531
   PubMed Web of Science ®Google Scholar
• KnoppRHDrug treatment of lipid disordersN Engl J Med199934149851110441607
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project Research GroupClofibrate and niacin in coronary heart diseaseJAMA19752313601088963
   PubMed Web of Science ®Google Scholar
• CarlsonLARosenhamerGReduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acidActa Med Scand19882234053287837
   PubMed Web of Science ®Google Scholar
• McKenneyJMJonesPHBaysHEComparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)Atherosclerosis200719243243717239888
   PubMed Web of Science ®Google Scholar
• CapuzziDMGuytonJRMorganJMEfficacy and safety of an extended-release niacin (Niaspan):a long-term studyAm J Cardiol19988274U81U
   PubMed Web of Science ®Google Scholar
• KamannaVSGanjiSHKashyapMLNiacin:an old drug rejuvenatedCurr Atheroscler Rep200911455119080727
   PubMed Web of Science ®Google Scholar
• BenyoZGilleAKeroJGPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushingJ Clin Invest20051153634264016322797
   PubMed Web of Science ®Google Scholar
• CarlsonLAOröLThe effect of nicotinic acid on the plasma free fatty acidsActa Med Scand196217264164514018702
   PubMed Web of Science ®Google Scholar
• CarlsonLANicotinic acid: the broad spectrum lipid drug. A 50th anniversary reviewJ Intern Med20052589411416018787
   PubMed Web of Science ®Google Scholar
• VanJTPanJWastyTComparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitusAm J Cardiol200289130612031735
   PubMed Web of Science ®Google Scholar
• DavidsonMHNovel nonstatin strategies to lower low-density lipoprotein cholesterolCurr Atheroscler Rep200911677019080731
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med20013451583159211757504
   PubMed Web of Science ®Google Scholar
• CannerPLBergeKHWengerNKFifteen year mortality in coronary drug project patients: long-term benefit with niacinJ Am Coll Cardiol1986812453782631
   PubMed Web of Science ®Google Scholar
• BlankenhornDHNessimSAJohnsonRLBeneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass graftsJAMA1987257323332403295315
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation20041103512351715537681
   PubMed Web of Science ®Google Scholar
• TaylorAJLeeHJSullenbergerLEThe effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3Curr Med Res Opin2006112243225017076985
   PubMedGoogle Scholar
• SinghIMShishehborMHAnsellBJHigh-density lipoprotein as a therapeutic target:a systematic reviewJAMA200729878679817699012
   PubMed Web of Science ®Google Scholar
• ZhaoXQMorseJSDowdyAASafety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)Am J Cardiol20049330731214759379
   PubMed Web of Science ®Google Scholar
• Rubenfire M Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspeciality on Patient Compliance to Treatment (IMPACT) StudyAm J Cardiol20049430631115276093
   PubMed Web of Science ®Google Scholar
• MorrowJDAwadJAOatesJAIdentification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humansJ Invest Dermatol1992988128151373750
   PubMed Web of Science ®Google Scholar
• IshidaHMasuhioYFukushimaAIdentification and characterization of novel isoforms of human DP-1:DP-1 (alpha) regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative mannerJ Biol Chem2005280246422464815863509
   PubMed Web of Science ®Google Scholar
• ChengKWuTJWuKKAntagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humansProc Natl Acad Sci U S A20061036682668716617107
   PubMed Web of Science ®Google Scholar
• JungnickelPWMaloleyPAVander TuinELPeddicordTECampbellJREffect of two aspirin pretreatment regimens on niacininduced cutaneous reactionsJ Gen Intern Med1997125915969346454
   PubMed Web of Science ®Google Scholar
• WilkinJKWilkinOKappRDonachieRChernoskyMEBucknerJAspirin blocks nicotinic acid-induced flushingClin Pharmacol Ther1982314784827060328
   PubMed Web of Science ®Google Scholar
• DunnRTForMARindoneJPKwiecinskiFALow-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administrationAm J Ther1995247848011850694
   PubMedGoogle Scholar
• GrundySMVegaGLMcGovernMEEfficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trialArch Intern Med2002162156812123399
   PubMed Web of Science ®Google Scholar
• CannerPLFurbergCDTerrinMLMcGovernMEBenefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Am J Cardiol20059525425715642562
   PubMed Web of Science ®Google Scholar
• DeanBJChangSSilva ElipeMVMetabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humansDrug Metab Dispos20073528329217132765
   PubMed Web of Science ®Google Scholar
• SturinoCFO’NeillGLachanceNDiscovery of a potent and selective PGD2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopentaindol-3-yl]-acetic acid (MK-0524)J Med Chem20075079480617300164
   PubMed Web of Science ®Google Scholar
• Van HeckenADepréMDe LepeleireIThe effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteersEur J Clin Pharmacol20076313514117200838
   PubMed Web of Science ®Google Scholar
• BindhuKMariaMScottBAbsorption, metabolism, and excretion of [14C]MK-0524, a prostaglandin D2 receptor antagonist, in humansDrug Metab Dispos200735119617431030
   PubMed Web of Science ®Google Scholar
• LaiEWenningLACrumleyTMPharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonistClin Pharmacol Ther20088384084717882161
   PubMed Web of Science ®Google Scholar
• DishyVLiuFEbelDLAtieeGJEffects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptomsJ Clin Pharmacol20094941642219246721
   PubMed Web of Science ®Google Scholar
• PapaliodisDBoucherWKempurajDNiacin-induced “flush” involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal modelJ Pharm Exp Ther2008327665672
   PubMed Web of Science ®Google Scholar
• FeltsASMolecule of the month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglyceridesCurr Top Med Chem200814131018928015
   PubMedGoogle Scholar
• MaccubbinDKorenMJDavidsonMFlushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular diseaseAm J Cardiol2009104748119576324
   PubMed Web of Science ®Google Scholar
• KushDHuDYYePFlushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patientsCardiology200911419219819602880
   PubMed Web of Science ®Google Scholar
• McKenneyJBaysHKorenMSafety profile of extended-release niacin/laropiprant in patients with dyslipidemia. Abstracts 77th Congress of the European Atherosclerosis SocietyAtherosclerosis Suppl200891194195
   Web of Science ®Google Scholar
• MaccubbinDBaysHEOlssonAgLipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemiaInt J Clin Pract2008621959197019166443
   PubMed Web of Science ®Google Scholar
• GleimGBallantyneCMLiuNEfficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemiaBr J Cardiol2009169097
   Google Scholar
• PaoliniJFMitchelYBReyesREffects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemiaAm J Cardiol200810162563018308010
   PubMed Web of Science ®Google Scholar
• BaysHEMaccubbinDMeehanAGBlood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patientsClin Ther20093111512219243712
   PubMed Web of Science ®Google Scholar
• BaysHERaderDJDoes nicotinic acid (niacin) lower blood pressureInt J Clin Pract20096315115919054161
   PubMed Web of Science ®Google Scholar